滔罗特用于预防胆囊结石复发的临床效果分析

目的 分析行保胆取石术的患者术后口服滔罗特对预防结石复发的效果,以及对不同种类结石的预防效果有何差异.方法 收集我院2010年3月~2012年10月行保胆取石术的患者共289例,其中给予术后口服滔罗特的174例,未服用滔罗特的115例,分别作为治疗组和对照组,随访1年,统计分析结石复发率.结果 在1年随访期内,治疗组复发5例,未复发169例,复发率为2.9%,对照组复发12例,未复发103例,复发率为10.4%,两组复发率有显著差异（P＜0.05）.对于胆固醇性结石,治疗组的复发率明显低于对照组（P＜0.05）;而对于胆色素性结石,两组复发率差异不显著（P＞0.05）.结论 术后口服滔罗特对降低结石复发率有一定积极作用,尤其对于胆固醇性结石效果较明显.

Clinical curative effect of TUDCA on the prevention of the relapse of cholecystolithiasis

Objective To analyze the curative effect of orally taking TUDCA in the patients receiving gallbladder-preserved lithotomy on the prevention of the relapse of cholecystolithiasis, and to find out the differences in the preventative effects on different kinds of calculi. Methods Totally 289 patients receiving the gallbladder-preserved lithotomy between March 2010 and October 2012 were selected,in which 174 cases orally took TUDCA after the operation, 115 ones did not take that medicine. Those two groups of patients were set as treatment and control groups, respectively. During the one-year follow-up, the relapse rate of calculus was statistically analyzed. Results During the one-year follow-up, there were 5 cases of relapse and 169 ones without relapse in the treatment group, and the relapse rate was 2.9%. In the control group, there were 12 cases of relapse and 103 ones without it, and the relapse rate was 10.4%. The relapse rate of cholesterol stone in the treatment group was significantly lower than that in the control group （ P 〈 0.05 ）. But there was no significant difference in the relapse rate of pigment calculus between the two groups. Conclusion Orally taking TUDCA after operation has a positive effect on reducing the relapse rate of calculus especially the cholesterol stone.